Balanced news tone
News Sentiment
PLRX sentiment intelligence
Pliant Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
51 relevant articles
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+2.7% over one week, -0.9% over four weeks, trend inactive, and below fair value.
Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
80/100 classification
One-week reaction
2.7%
Price confirming higher
Trend fit
Trend inactive
-0.9% over four weeks
Fair value
-85.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
37
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Investing.com Nigeria
Direct company coverage
Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com
This article reports on a Form 4 filing for Pliant Therapeutics Inc (PLRX) for July 13. Form 4s detail changes in beneficial ownership of company stock by insiders. The article, however, does not provide specific details from the Form 4 filing itself beyond noting its existence.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 23:42
- Source
- Investing.com Nigeria
Moomoo
Direct company coverage
Press Release: Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Pliant Therapeutics has announced the appointment of Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments are expected to strengthen the company's strategic leadership as it continues to advance its therapeutic pipeline.
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 13 Jul 2026 21:10
- Source
- Moomoo
Stock Titan
Direct company coverage
[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event
Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members on July 9, 2026, appointing Robert Iannone, M.D., M.S.C.E. and Flavia Borellini, Ph.D. as independent directors. Both new directors receive annual retainers and stock options, with Dr. Borellini
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 13 Jul 2026 20:42
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pliant Therapeutics (PLRX) director files initial insider ownership statement
Pliant Therapeutics director Borellini Flavia has filed an initial statement of beneficial ownership (Form 3) as a director according to an SEC filing. The filing indicates no equity transactions or derivative positions, solely disclosing her insider status. This is a neutral fil
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:42
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pliant Therapeutics (NASDAQ: PLRX) grants 60,000 options to director Iannone
Pliant Therapeutics (NASDAQ: PLRX) has granted 60,000 stock options to director Robert Iannone on July 9, 2026. The options have an exercise price of $1.13 per share and will expire on July 9, 2036. The vesting schedule dictates that 1/36th of the options will vest monthly, conti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:42
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3
Pliant Therapeutics, Inc. (PLRX) director Robert Iannone has submitted an initial statement of beneficial ownership on Form 3. The filing indicates no reported transactions such as purchases, sales, or derivative exercises by Iannone. This Form 3 filing serves to officially discl
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:42
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini
Pliant Therapeutics (PLRX) has granted 60,000 stock options to director Flavia Borellini. The options, with an exercise price of $1.13 per share and an expiration date of July 9, 2036, will vest monthly over a 36-month period, contingent on her continued service. This grant is a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:42
- Source
- Stock Titan
Investing News Network
Direct company coverage
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Pliant Therapeutics has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments bring extensive global oncology drug development, regulatory, and operational expertise to the company. The new board members are expected
- Tone
- Positive 73/100
- Event
- Regulatory and legal
- Published
- 13 Jul 2026 14:42
- Source
- Investing News Network
Investing.com
Direct company coverage
Pliant Therapeutics adds two directors with oncology expertise
Pliant Therapeutics, Inc. has expanded its Board of Directors with the appointment of Dr. Flavia Borellini and Dr. Robert Iannone, both bringing extensive oncology drug development experience. The company is a clinical-stage biopharmaceutical firm currently developing integrin-ba
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 13 Jul 2026 13:40
- Source
- Investing.com
Stock Titan
Direct company coverage
Two cancer drug veterans join Pliant Therapeutics’ board to guide PLN-101095
Pliant Therapeutics (Nasdaq: PLRX) has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments bring extensive global oncology drug development, regulatory, and operational expertise to the company as it advances its in
- Tone
- Positive 71/100
- Event
- Regulatory and legal
- Published
- 13 Jul 2026 12:40
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Price to sales forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX
This page provides financial data, specifically the price to sales forward, for Pliant Therapeutics, Inc. (NASDAQ: PLRX). It details no trades, indicating a market closure, and highlights access to various financial tools and market data services.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 10:39
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Pliant Therapeutics, Inc. – FWB:9PT
This article provides the "Price to earnings forward" for Pliant Therapeutics, Inc. (FWB:9PT) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades recorded. The content is primarily a data point rather than an analytical article.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jul 2026 07:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – FWB:9PT
This article provides a financial overview and enterprise value to revenue forward for Pliant Therapeutics, Inc. (FWB:9PT) on the Frankfurt Stock Exchange. It indicates no recent trades for the company and is part of a larger financial data and trading platform.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jul 2026 00:39
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Pliant Therapeutics, Inc. – TRADEGATE:9PT
This article provides a financial overview of Pliant Therapeutics, Inc. (TRADEGATE:9PT), focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing that no trades have occurred and the market is closed for
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 20:10
- Source
- TradingView
dars.gov.et
Direct company coverage
Pliant Therapeutics (PLRX) Stock Edges Lower, Holds Closely Above Key Support - Accumulation Line
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 09 Jul 2026 16:43
- Source
- dars.gov.et
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX
This article provides access to the "Enterprise value to EBITDA forward"
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – GETTEX:9PT
This article displays the "Enterprise value to EBITDA forward" metric for Pliant Therapeutics, Inc. (GETTEX:9PT) on TradingView. It appears to be a financial data page rather than a descriptive article, showing no specific value for the metric but presenting the company's financi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 07:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX
The article focuses on Pliant Therapeutics, Inc. (NASDAQ: PLRX) and its enterprise value to EBIT forward. It presents financial data related to the company within the TradingView platform, noting that the market was closed at the time of viewing with no trades. The content primar
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 01:10
- Source
- TradingView
Intellectia AI
Direct company coverage
PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an analysis of Pliant Therapeutics Inc. (PLRX) financials, focusing on its revenue, profitability margins (gross, operating, net), and Return on Equity. It also benchmarks PLRX against competitors IMMP and XBIT, highlighting its market capitalization and com
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 03:10
- Source
- Intellectia AI
TradingView
Direct company coverage
Pliant Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLRX)
This article provides financial actuals and estimates for Pliant Therapeutics, Inc. (NASDAQ:PLRX), highlighting its current stock price, market capitalization, and analyst forecasts. It includes details on past performance, revenue, earnings, and upcoming earnings report dates, e
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 02:09
- Source
- TradingView
TradingView
Direct company coverage
9PT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Pliant Therapeutics, Inc. (9PT) stock, including analyst price targets, historical highs and lows, and upcoming earnings dates. It also details the company's financial performance, such as EPS, revenue, and net income, and confirms that 9PT do
- Tone
- Positive 60/100
- Event
- Earnings
- Published
- 25 Jun 2026 22:41
- Source
- TradingView
TradingView
Direct company coverage
PLRX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Pliant Therapeutics, Inc. (PLRX) stock, including analyst price targets and ratings. It details the company's current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also includes a brief FAQ
- Tone
- Negative 40/100
- Event
- Analyst action
- Published
- 25 Jun 2026 14:40
- Source
- TradingView
TradingKey
Direct company coverage
Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Pliant Therapeutics Inc (PLRX), stating that relevant financial data for FY2024 and FY2025 has not yet been disclosed by the company. It primarily highlights the lack of available information regarding revenue by regio
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 17:10
- Source
- TradingKey
TradingKey
Direct company coverage
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings
The article details the shareholder structure of Pliant Therapeutics Inc (PLRX), identifying its major shareholders and institutional holdings. It lists the top individual shareholders like Tang Capital Management and Citadel Advisors, along with their respective proportions. The
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:39
- Source
- TradingKey
TradingKey
Direct company coverage
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pliant Therapeutics Inc (PLRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 23:10
- Source
- TradingKey
TradingKey
Direct company coverage
Pliant Therapeutics Inc (PLRX) Institutional Confidence
Pliant Therapeutics Inc (PLRX) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.81%, a 4.56% decrease quarter-over-quarter. James Simons is the largest institutional shareh
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 23:10
- Source
- TradingKey
TradingKey
Direct company coverage
Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Pliant Therapeutics Inc (PLRX) as of June 17, 2026. The company currently holds a valuation score of 8.42, ranking 96 out of 157 in the Pharmaceuticals industry. Key financial ratios like P/E, P/B, P/S, and P/CF are mentioned, though
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 22:40
- Source
- TradingKey
TradingKey
Direct company coverage
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Pliant Therapeutics Inc (PLRX) has an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $3.50, with a range from $2.00 to $4.00, indicating a potential upside of 124.09%. The company's stock
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 17 Jun 2026 19:11
- Source
- TradingKey